ライフサイエンスコーパス: biological drug

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 as a well-characterized pharmaceutical-grade biological drug.

2 important in diseases and in formulations of biological drugs.

3 ients with rheumatoid arthritis who received biological drugs.

4 ble routes to addressing those diseases with biological drugs.

5 isk of serious infections, although low-dose biological drugs (0.93, 0.65-1.33) were not.

6 ible interval [CrI] 1.09-1.58) and high-dose biological drugs (1.90, 1.50-2.39) were associated with

7 clusion if they included any of the approved biological drugs and reported serious infections.

8 used for a new chemical drug, NBE for a new biological drug, and the combined designation NTE should

9 Evidence is inconsistent as to whether biological drugs are associated with an increased risk o

10 d with traditional DMARDs, although low-dose biological drugs are not.

11 , over 90% of patients who were prescribed a biological drug (BD) have undergone serological screenin

12 ase (AD), leading to many small-molecule and biological drug candidates.

13 serious infections in patients treated with biological drugs compared with those treated with tradit

14 h rheumatoid arthritis who were treated with biological drugs, compared with those treated with tradi

15 transition metal catalysts, nanocarriers for biological drug delivery, and sensors for volatile organ

16 D-experienced or anti-tumour necrosis factor biological drug-experienced patients.

17 ivation and suggest that IL-4 is a potential biological drug for treating MI.

18 o invent a novel method to produce synthetic biological drugs from engineered MSCs.

19 de an understanding of the immunogenicity of biological drug molecules.

20 pared with traditional DMARDs, standard-dose biological drugs (OR 1.31, 95% credible interval [CrI] 1

21 Biological drug potency is not the sole determinant of b

22 broadly assign immunogenicity risk levels to biological drug products, and present risk level-based '

23 , immunogenicity, and safety to the original biological drugs-provide opportunities both to improve h

24 y of normal small molecular weight drugs and biological drugs such as peptide and proteins.

25 upon effective treatment with etanercept, a biological drug targeting the TNF pathway and suppressin

26 New classes of biological drugs that block the production or action of

27 s and proteins is critical to the success of biological drug therapies.

28 each year ranged from six for standard-dose biological drugs to 55 for combination biological therap

29 New biological drugs to treat cancer can cause autoimmune hy

30 arthritis, receiving conventional IT and/or biological drugs were tested for markers of infection.

31 Standard-dose and high-dose biological drugs (with or without traditional DMARDs) ar

32 Antibodies are a highly successful class of biological drugs, with over 50 such molecules approved f

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。